Analysis of Harvest Moon's corporate history, corporate relationships, biosimilars development pipeline, and Datamonitor's evaluation of the company's strategy and key strengths, weaknesses, opportunities and threats.
This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's biosimilars portfolio, including analysis of key product profiles, examining key drivers and resistors to development, market sizing, specifics of development such as clinical trials (where available) for each key biosimilar molecule in development.
FEATURES AND BENEFITS
Strategic insight into the key strategies that have shaped the company's progress and/or will define its outlook going forward.
Provides an indication of how biosimilars fit into the wider company context, and a history of deals & alliances.
Harvest Moon specializes in the development of complex generics and biosimilars. These products are in-licensed from emerging market copy-biologic developers before they are out-licensed to partners in developed markets, with Harvest Moon's receiving royalties. Harvest Moon has 30 biosimilar products in various stages of development.
YOUR KEY QUESTIONS ANSWERED
See how Harvest Moon relies on corporate relationships for both sourcing products and commercialization
Evaluate key products in Harvest Moon's pipeline, which is one of the largest monoclonal antibody biosimilar pipelines globally
Table of Contents
Table of Contents
ABOUT THIS REPORT
PharmaVitae Explorer database
Harvest Moon biosimilars SWOT analysis
Harvest Moon plans to use simple biologic products to gain market experience
Harvest Moon operates a virtual biotech model
Low-cost products can be sourced from China and Taiwan
Sales agreements facilitate market entry
Phase I trials offered as optional add-on
Products can be launched in emerging markets while waiting for mature market access
Harvest Moon biosimilar portfolio
Human insulin market size
Insulin glargine and lispro
Insulin glargine and lispro market size
Erythropoietin market size
Filgrastim and pegfilgrastim
Filgrastim and pegfilgrastim market size
Etanercept market size
Imiglucerase market size
Interferon beta-1a and -1b
Interferon beta market size
Deals and alliances
Table: Harvest Moon - biosimilar portfolio
Table: Forecasted human insulin sales in the seven major markets ($m), 2011-16
Table: Biosimilar human insulin, products currently launched or in development
Table: Forecasted lispro and glargine insulin sales ($m), 2011-16
Table: Biosimilar human insulin, insulin glargine, and insulin lispro products currently launched or in development
Table: Forecasted epoetin and darbepoetin sales ($m), 2011-16
Table: Harvest Moon - pipeline and marketed biosimilar epoetin drugs
Table: Forecasted filgrastim and pegfilgrastim sales ($m), 2011-16
Table: Harvest Moon - pipeline and marketed biosimilar filgrastim and pegfilgrastim drugs